{"name":"William Ondo, MD","slug":"william-ondo-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Apomorphine Sublingual Film","genericName":"Apomorphine Sublingual Film","slug":"apomorphine-sublingual-film","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Apomorphine Sublingual Film","genericName":"Apomorphine Sublingual Film","slug":"apomorphine-sublingual-film","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxORjZETkVJYjI0X0M0Rno4QVh5cHA3M1p6OFZzOHgyaE0zOUNuTVY1emY5QVJoNUs0ZUdkTUJia0VVYzNVVjVkVXpyUXpsU0lKeFBFV005V1FCbV95OFllVjhKZFpnSUl5VGQzU3pfdnVielFxTW1xRlU1THVTcGgtdDVXdG10VXMzXzFkWGZ2aENEV21xa2NmMU14QQ?oc=5","date":"2025-06-30","type":"pipeline","source":"neurologylive.com","summary":"Understanding the Phenomenology and Impact of Psychosis in Parkinson Disease: William Ondo, MD - neurologylive.com","headline":"Understanding the Phenomenology and Impact of Psychosis in Parkinson Disease: William Ondo, MD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxNQWRXMjlqT0ZQN1FTeTNKaDlnOVdxMk9Qb2hZVGNQbmp2QjVxRExsZkxRd2s0cUNBMjNiYjZRczZtVjJJaXBlWGJmMERBQWhNY2c1TTZrNTJxckxiT2NEdDNWTFRxa2RxdnZLdlNfS0pZR1VudFI4Y04ySjMyNWdFT3RJTzBfd3dWRXI0NWR6N0xvZkRPU2N0MDVSWk51RTFBMkIwaENpN3J6bmRJZnBHV2dvRlRRNWJud0paUXFXTlVJWkNoVzJYa1NLbmw?oc=5","date":"2024-08-08","type":"regulatory","source":"neurologylive.com","summary":"FDA Approves Carbidopa/Levodopa ER Capsules Formulation IPX203 for Parkinson Disease - neurologylive.com","headline":"FDA Approves Carbidopa/Levodopa ER Capsules Formulation IPX203 for Parkinson Disease","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPOVJxSmExaEItRHExQVowSFVIbEFHTmxUWWhNcllfcnZacG80V2czR19WU051TVUyWDVvdkZsTkgzTVZjVFhCOTJoSlRER1liMnNVWlB5SFJqVFF1VEp1MElPSHNfWF9aNmF4S3pCZVp0Sng2bkplaGxGQmJkNTFaTXlFSkZXWkJ0aXJiOA?oc=5","date":"2024-04-14","type":"pipeline","source":"neurologylive.com","summary":"Extended Use of Investigational Agent IPX203 Safe in Parkinson Disease - neurologylive.com","headline":"Extended Use of Investigational Agent IPX203 Safe in Parkinson Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBpVHdULUdMQ3dNc3ljaGI1RE1PMXBGRkJfRklHcksyMzRhU0FKUVpUOG1iMi1oMTBTQkRIVjVIMnkwMk81YkFHZk1hVjk5czViUWdIblgtZjVZMFVMYU45X3Z4TDFjSHhTMUE?oc=5","date":"2023-12-15","type":"trial","source":"Neurology® Journals","summary":"Randomized controlled trial of deutetrabenazine for tardive dyskinesia - Neurology® Journals","headline":"Randomized controlled trial of deutetrabenazine for tardive dyskinesia - Neurology® Journals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE5qYzBfRTFWMUJrOENzdHRmQ0V6OWVsb0w4ZUZjQklwOG1abG55S0Z3VXR1bEtfMy1iWDdvRGRabDVCaEZpWUVkbEk2azZTMEV4OEJ3eEdsbG1zQ01ZMVdDWjdZdXF1cWpiUFhBTFNjaHdlQkU?oc=5","date":"2019-03-08","type":"regulatory","source":"Psychiatry Online","summary":"Systematic Literature Review of Quetiapine for the Treatment of Psychosis in Patients With Parkinsonism - Psychiatry Online","headline":"Systematic Literature Review of Quetiapine for the Treatment of Psychosis in Patients With Parkinsonism","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPRDZMcjBJVU5La3gtaGRQT1F2YVpDV1p5ZFJfdXNaSUw4YmJKQ2ZZbFl0OXNqdDM0WHM0N3RlSjhrVlYwMW9FbFYzV1hKX2g2T1Nlb3I3Y2VxRjM0VlR0N1ZOWThDa0FkZFZMRDQzcW9ZZlFRRVk4b05qd20yUUxRUGZoRVhmckpIaTZHaWY4N2xLZnNsVUpnY3UzY2FRSThaTC0zOVhFZFFOUUxZSE1VeHRnTHViMEk5dHMyaFVNYWFOMnE3R2Q4akJ3bWw?oc=5","date":"2017-12-05","type":"pipeline","source":"Sleep Review","summary":"Differentiating the Diagnosis of RLS: William G. Ondo, MD - Sleep Review","headline":"Differentiating the Diagnosis of RLS: William G. Ondo, MD","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":7,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}